Abstract
Boys with fragile X syndrome (FXS), the leading known genetic cause of autism spectrum disorder (ASD), demonstrate significant impairments in social gaze and associated weaknesses in communication, social interaction, and other areas of adaptive functioning. Little is known, however, concerning the impact of behavioral treatments for these behaviors on functional brain connectivity in this population. As part of a larger study, boys with FXS (mean age 13.23 +/- 2.31 years) and comparison boys with ASD (mean age 12.15 +/- 2.76 years) received resting-state magnetic resonance imaging scans prior to and following social gaze training administered by a trained behavior therapist in our laboratory. Network-agnostic connectome-based predictive modeling (CPM) of pre-treatment RSFC data revealed a set of positive (FXS > ASD) and negative (FXS < ASD) edges that differentiated the groups significantly and consistently across all folds of cross-validation. Following administration of the brief training, the FXS and ASD groups demonstrated normalization of connectivity differences. The divergence in the spatial pattern of normalization response, based on functional connectivity differences pre-treatment, suggests a unique pattern of response to treatment in the FXS and ASD groups. These results support using connectome-based predictive modeling as an outcome measure in clinical trials.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02616796
Funding Statement
This work was supported by the Eunice KennedyShriver National Institute of Child Health and Human Development at the National Institutes of Health (award number R01HD081336) to SH. Additional support was provided by the National Institutes of Health (R00MH104605, DP2MH119735) to M.S.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Stanford University School of Medicine Institutional Review Board approved all study procedures.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data sharing statement: The final dataset will be stripped of all identifiers and made available to qualified investigators upon request.
Data Availability
The final dataset will be stripped of all identifiers and made available to qualified investigators upon request.
